HDL as a target in the treatment of atherosclerotic cardiovascular disease (Q36058450)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	HDL as a target in the treatment of atherosclerotic cardiovascular disease	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

1 reference

Europe PubMed Central

HDL as a target in the treatment of atherosclerotic cardiovascular disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

atherosclerosis

1 reference

based on heuristic

inferred from title

cardiovascular disease

1 reference

based on heuristic

inferred from title

Patrick Linsel-Nitschke

1

object named as

Patrick Linsel-Nitschke

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

author name string

Alan R Tall

2

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

193-205

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Serum Lipoproteins and Coronary Heart Disease in a Population Study of Hawaii Japanese Men

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Prevalence of risk factors in men with premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The Prospective Cardiovascular Münster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Lipoproteins, cardiovascular disease, and death. The Framingham study

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Cardiovascular Health in Childhood: A Statement for Health Professionals From the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Mortality by cause for eight regions of the world: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI–dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The role of high-density lipoproteins in oxidation and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

HDL and arteriosclerosis: beyond reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

No effect of fibrates on synthesis of apolipoprotein(a) in primary cultures of cynomolgus monkey and human hepatocytes: apolipoprotein A-I synthesis increased

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Molecular identification of high and low affinity receptors for nicotinic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifi

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Obesity and the regulation of energy balance

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Increased CD36 protein as a response to defective insulin signaling in macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The role of endothelial insulin signaling in the regulation of vascular tone and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The mechanisms of action of PPARs

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Peroxisome proliferator-activated receptors in macrophage biology: friend or foe?

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The implications of the structure of the bactericidal/permeability-increasing protein on the lipid-transfer function of the cholesteryl ester transfer protein

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The safety and immunogenicity of a CETP vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Interaction of CETP inhibitory peptide and lipoprotein substrates in cholesteryl ester transfer assay: relationship between association properties and inhibitory activities.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic Rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Intravenous Injection of Rabbit Apolipoprotein A-I Inhibits the Progression of Atherosclerosis in Cholesterol-Fed Rabbits

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

High-density lipoproteins as an emerging therapeutic target for atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I(Milano).

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Inhibition of arterial thrombus formation by ApoA1 Milano

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Nuclear receptor regulation of cholesterol and bile acid metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Nuclear receptors and lipid physiology: opening the X-files

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Expression of the liver X receptor alpha and beta in embryonic and adult mice.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Synthetic LXR ligand inhibits the development of atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Identification of macrophage liver X receptors as inhibitors of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Molecular determinants for the tissue specificity of SERMs

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Retinoic Acid Receptor-Mediated Induction of ABCA1 in Macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A novel endothelial-derived lipase that modulates HDL metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Synthesis and pharmacological studies of 3-amino-2-methyl-1-phenyl-propanones as hypolipidemic agents in rodents

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Induction of adrenal scavenger receptor BI and increased high density lipoprotein-cholesteryl ether uptake by in vivo inhibition of hepatic lipase

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Expression and activation of the farnesoid X receptor in the vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Chemical genomics: functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor un

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

High-density lipoprotein stimulates myocardial perfusion in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

Phospholipid liposomes acquire apolipoprotein E in atherogenic plasma and block cholesterol loading of cultured macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

31 March 2020

ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1658

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/NRD1658

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36058450&oldid=2198138600"